Agenus (AGEN) shares slipped in morning trade after the company missed fourth quarter revenue estimates. The company reported ...

Q4 2024 Earnings Call Transcript March 11, 2025 Agenus Inc. beats earnings expectations. Reported EPS is $-2.04, expectations ...

Baird lowered the firm’s price target on Agenus (AGEN) to $3 from $6 and keeps a Neutral rating on the shares. The firm updated its model ...

Agenus Inc (AGEN) reports reduced operational burn and promising clinical developments, despite a significant net loss and ...

Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company advancing innovative cancer therapies, ...

Reports Q4 revenue $26.84M, consensus $30.09M. “In line with our strategic objectives, we significantly reduced our annualized operational burn ...

LEXINGTON, Mass. (AP) — LEXINGTON, Mass. (AP) — Agenus Inc. (AGEN) on Tuesday reported a loss of $46.8 million in its fourth quarter. The Lexington, Massachusetts-based company said it had a loss of ...

Agenus Inc. (NASDAQ:AGEN – Get Free Report) has earned a consensus rating of “Hold” from the six brokerages that are ...

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today highlights key scientific contributions in 2024-2025 that are shaping the future of cancer immunotherapy. Agenus is ...

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its fourth quarter and year end 2024 ...

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented data at the American Association for Cancer Research (AACR) IO Annual Meeting ...

Good morning, and welcome to Agenus Inc.'s fourth-quarter and year-end 2024 earnings conference call. Currently, all ...